OKYO Pharma Limited

DB:OK10 Stock Report

Market Cap: €38.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

OKYO Pharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Gary Jacob

Chief executive officer

UK£1.2m

Total compensation

CEO salary percentage29.2%
CEO tenure2.6yrs
CEO ownershipn/a
Management average tenure2.6yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Gary Jacob's remuneration changed compared to OKYO Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023UK£1mUK£351k

-UK£13m

Dec 31 2022n/an/a

-UK£11m

Sep 30 2022n/an/a

-UK£7m

Jun 30 2022n/an/a

-UK£5m

Mar 31 2022UK£2mUK£266k

-UK£5m

Dec 31 2021n/an/a

-UK£5m

Sep 30 2021n/an/a

-UK£4m

Jun 30 2021n/an/a

-UK£3m

Mar 31 2021UK£633kUK£62k

-UK£3m

Compensation vs Market: Gary's total compensation ($USD1.53M) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.

CEO

Gary Jacob (76 yo)

2.6yrs

Tenure

UK£1,202,916

Compensation

Dr. Gary S. Jacob, PhD, served as an Independent Director at Virpax Pharmaceuticals, Inc. since April 2020 until July 25, 2022. He had been an Independent Director of Cardiff Oncology, Inc. since February...

Leadership Team

NamePositionTenureCompensationOwnership
Gary Jacob
CEO & Executive Director2.6yrsUK£1.20mno data
Michael Beck
Founderno datano datano data
Keeren Shah
Chief Financial Officer3yrsno data0%
€ 0
Rajkumar Patil
Chief Scientific Officer2.4yrsno data0%
€ 0

2.6yrs

Average Tenure

65yo

Average Age

Experienced Management: OK10's management team is considered experienced (2.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gary Jacob
CEO & Executive Director2.6yrsUK£1.20mno data
Bernard Denoyer
Independent Non-Executive Director1.7yrsUK£46.20kno data
Gabriele Marco Cerrone
Non-Executive Chairman2.6yrsUK£360.71kno data
John Brancaccio
Independent Non-Executive Director3.2yrsUK£51.07kno data
Jay Pepose
Member of Scientific Advisory Boardless than a yearno datano data
Willy Simon
Senior Independent Non-Executive Director7.8yrsUK£31.61kno data
Napoleone Ferrara
Member of Scientific Advisory Board3yrsno datano data
Pedram Hamrah
Member of Scientific Advisory Boardno datano datano data

2.6yrs

Average Tenure

72yo

Average Age

Experienced Board: OK10's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/08/21 12:33
End of Day Share Price 2023/05/24 00:00
Earnings2023/03/31
Annual Earnings2023/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

OKYO Pharma Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yi ChenH.C. Wainwright & Co.
Ashok KumarThinkEquity LLC